Deborah Watkins Bruner on Side Effects From Platinum-Based Drugs in Ovarian Cancer

The increasing use of biosimilars makes prophylaxis with growth factor more cost effective.

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

Electronic patient-reported outcomes may have a place in high-quality cancer care, according to investigators.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Nurses can be empowered to advocate for methylene blue therapy as an effective oral mucositis pain relief treatment.

Data from a single-institution study showed that 98.6% of their patients with head and neck cancer experienced oral mucositis.